AIRLINK 80.55 Increased By ▲ 1.14 (1.44%)
BOP 5.28 Decreased By ▼ -0.05 (-0.94%)
CNERGY 4.39 Increased By ▲ 0.01 (0.23%)
DFML 34.79 Increased By ▲ 1.60 (4.82%)
DGKC 76.90 Increased By ▲ 0.03 (0.04%)
FCCL 20.65 Increased By ▲ 0.12 (0.58%)
FFBL 33.50 Increased By ▲ 2.10 (6.69%)
FFL 9.75 Decreased By ▼ -0.10 (-1.02%)
GGL 10.20 Decreased By ▼ -0.05 (-0.49%)
HBL 118.45 Increased By ▲ 0.52 (0.44%)
HUBC 135.60 Increased By ▲ 1.50 (1.12%)
HUMNL 7.04 Increased By ▲ 0.04 (0.57%)
KEL 4.67 No Change ▼ 0.00 (0%)
KOSM 4.70 Decreased By ▼ -0.04 (-0.84%)
MLCF 37.60 Increased By ▲ 0.16 (0.43%)
OGDC 137.00 Increased By ▲ 0.30 (0.22%)
PAEL 23.04 Decreased By ▼ -0.11 (-0.48%)
PIAA 27.17 Increased By ▲ 0.62 (2.34%)
PIBTL 6.91 Decreased By ▼ -0.09 (-1.29%)
PPL 113.40 Decreased By ▼ -0.35 (-0.31%)
PRL 27.49 Decreased By ▼ -0.03 (-0.11%)
PTC 14.75 No Change ▼ 0.00 (0%)
SEARL 57.00 Decreased By ▼ -0.20 (-0.35%)
SNGP 66.67 Decreased By ▼ -0.83 (-1.23%)
SSGC 11.05 Decreased By ▼ -0.04 (-0.36%)
TELE 9.27 Increased By ▲ 0.04 (0.43%)
TPLP 11.58 Increased By ▲ 0.02 (0.17%)
TRG 71.92 Decreased By ▼ -0.18 (-0.25%)
UNITY 25.60 Increased By ▲ 0.78 (3.14%)
WTL 1.36 Decreased By ▼ -0.04 (-2.86%)
BR100 7,590 Increased By 64.4 (0.86%)
BR30 24,769 Increased By 119.8 (0.49%)
KSE100 72,446 Increased By 474.4 (0.66%)
KSE30 23,926 Increased By 177.4 (0.75%)

GENEVA: The AstraZeneca-Oxford Covid-19 vaccine can be used for people aged over 65, and also where coronavirus variants of concern are circulating, WHO experts said Wednesday, soothing fears about the jab.

The World Health Organization’s 15-member Strategic Advisory Group of Experts on Immunization (SAGE) issued interim recommendations for when and how to use the two-shot vaccine, which has yet to receive WHO emergency use authorisation.

The announcement came after the vaccine suffered several setbacks, raising questions about whether it was appropriate to use it on older people, or in places where a variant of the virus first found in South Africa is circulating.

SAGE chief Alejandro Cravioto acknowledged the lack of data on the vaccine’s efficacy for people aged over 65, which has prompted a number of countries to withhold recommending its use in older people — who are by far the most vulnerable to the virus.

But, he told journalists, “we feel that the response of this group cannot be any different from groups of a younger age”.

SAGE, he said, recommends “for the vaccine to be used for 18 years and above without an upper age limit”.

He said the experts were eagerly awaiting more specific data on the efficacy of the vaccine in people over 65, but said it “would not be appropriate” to wait with its recommendations.

“We have thousands of people dying,” he stressed.

Comments

Comments are closed.